Stockscreener 앱 받기
8.05
2.16%
0.17
시간 외 거래:
8.04
-0.01
-0.12%
Corbus Pharmaceuticals Holdings Inc 주식(CRBP)의 최신 뉴스
Corbus Pharmaceuticals Holdings Inc. stock rises Monday, still underperforms market - MarketWatch
Corbus Pharmaceuticals Stock (US21833E1038): Nasdaq price action in focus on a quiet news day - AD HOC NEWS
Corbus Pharmaceuticals Holdings Inc. stock outperforms competitors on strong trading day - MarketWatch
Corbus Pharmaceuticals Holdings Inc. stock rises Thursday, still underperforms market - MarketWatch
Corbus Pharmaceuticals (CRBP) director sells 2,026 shares under 10b5-1 plan - Stock Titan
Corbus (NASDAQ: CRBP) director sells 2,412 shares under 10b5-1 plan - Stock Titan
Corbus (CRBP) director Jenkins sells 4,800 shares in Rule 10b5-1 trade - Stock Titan
Corbus Pharmaceuticals teases cancer, obesity data as key clinical readouts near - MSN
Corbus Pharmaceuticals Holdings Inc. stock underperforms Tuesday when compared to competitors despite daily gains - MarketWatch
Corbus Pharmaceuticals targets HPV-linked head and neck cancer with CRB-701 study - MSN
Corbus Pharmaceuticals Teases Cancer, Obesity Data as Key Clinical Readouts Near - Yahoo Finance
Liquidity Mapping Around (CRBP) Price Events - Stock Traders Daily
Insider Spends US$101k Buying More Shares In Corbus Pharmaceuticals Holdings - simplywall.st
Corbus Pharmaceuticals Holdings Inc. stock underperforms Friday when compared to competitors - MarketWatch
CRBP: Lead oncology and obesity assets advance with pivotal data and strong financial runway - TradingView
symbol__ Stock Quote Price and Forecast - CNN
Corbus Pharmaceuticals CBO Nishant Saxena buys $101,218 in stock By Investing.com - Investing.com India
CRBP Earning Date, Earning Analysis and Earning Prediction - Intellectia AI
Corbus Pharmaceuticals CBO Nishant Saxena buys $101,218 in stock - Investing.com
Insider Purchase: Chief Business Officer of $CRBP Buys 9,000 Shares - Moomoo
Corbus (CRBP) Chief Business Officer buys 13,500 shares in open market - Stock Titan
Corbus Pharmaceuticals Holdings Inc. stock underperforms Wednesday when compared to competitors - MarketWatch
Guggenheim Maintains Corbus Pharmaceuticals(CRBP.US) With Buy Rating, Maintains Target Price $45 - Moomoo
Corbus Pharmaceuticals Holdings Inc. stock outperforms competitors despite losses on the day - MarketWatch
A Quick Look at Today's Ratings for Corbus Pharmaceuticals(CRBP.US), With a Forecast Between $40 to $54 - Moomoo
Corbus Pharmaceuticals Holdings Inc. stock underperforms Monday when compared to competitors - MarketWatch
Corbus Pharmaceuticals Targets HPV-Linked Head and Neck Cancer With CRB-701 Study - Yahoo Finance
Corbus Pharmaceuticals Holdings, Inc. (CRBP) Stock Price Today & Analysis - Gotrade
CRBP Q1 2026 Earnings: Narrower Loss Misses on Thin Volume; No Revenue YetWeak Earnings Momentum - thelegaladvocate.com
Corbus Pharmaceuticals Holdings Inc. stock underperforms Thursday when compared to competitors - MarketWatch
Analysts Are Bullish on Top Healthcare Stocks: Eli Lilly & Co (LLY), Corbus Pharmaceuticals (CRBP) - The Globe and Mail
Why (CRBP) Price Action Is Critical for Tactical Trading - Stock Traders Daily
RBC Capital Maintains Corbus Pharmaceuticals(CRBP.US) With Buy Rating, Cuts Target Price to $36 - Moomoo
TNXP Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
CRBP Maintained by Wedbush -- Price Target Lowered to $30 - GuruFocus
Mizuho Securities Maintains Corbus Pharmaceuticals(CRBP.US) With Buy Rating, Maintains Target Price $44 - Moomoo
Corbus Pharmaceuticals: I'd Preach Caution After Selloff On Latest Data Drop (NASDAQ:CRBP) - Seeking Alpha
LifeSci Capital Maintains Corbus Pharmaceuticals(CRBP.US) With Buy Rating, Maintains Target Price $38 - Moomoo
Corbus Pharmaceuticals Holdings Inc. stock underperforms Tuesday when compared to competitors - MarketWatch
Corbus Pharmaceuticals Falls on Reports of Adverse Events in Tumor-Treatment Study - Moomoo
Corbus Pharmaceuticals (CRBP) Analyst Sees Mispriced Weakness - GuruFocus
Corbus Pharmaceuticals (CRBP) Reports Promising Data on CRB-701 Trial - GuruFocus
Corbus Pharmaceuticals Stock (CRBP) Opinions on Updated CRB-701 Cancer Data Release - Quiver Quantitative
CRBP Reiterated by HC Wainwright & Co. -- Price Target Maintained at $40 - GuruFocus
12 Health Care Stocks Moving In Tuesday's Intraday Session - Benzinga
CRB-701 Phase 1/2 data outlines next steps, Corbus Pharmaceuticals Holdings, Inc. - Traders Union
Corbus Pharma (CRBP) Faces Premarket Decline Following Phase 1/2 Trial Data - GuruFocus
Corbus Pharmaceuticals Holdings, Inc. (CRBP) Discusses Clinical Data Update From Phase 1/2 Study of CRB-701 Presented at ASCOSlideshow (NASDAQ:CRBP) 2026-05-26 - Seeking Alpha
Corbus Pharmaceuticals stock falls on trial data release By Investing.com - Investing.com South Africa
2.60%
0.94%
자본화:
|
볼륨(24시간):